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     AITP mostly occur in children accompanied by variable clinical sings including petechiae, 
purpura, ecchymosis and severe bleeding. This study has determined and characterized the anti-
platelet glycoproteins in children with ITP. The aim of this study was to determinate anti-
platelet glycoproteins (GPs) using MAIPA method. During 18 months 38 children with clinical 
signs of AITP were studied in Mofid children hospital. To determine anti-platelet antibodies by 
ELISA technique, washed O negative platelets were used as a source of platelet antigens. 
MAIPA method was used to detect antibodies against individual platelet membrane 
glycoprotein. The anti-platelet antibodies level above mean+ 3SD of control group was assumed 
as positive. The results indicated that the platelet count ranges was between 2×109/L and 
95×109/L. 63.5 % out of 38 patients were anti-platelet antibodies positive with ELISA method. 
The correlation between the above patients with anti-platelet antibody positive and clinical signs 
was 0.4. Results for determination of antibody against platelet GPIIb/IIIa, GPIb/IX and GPIa/IIa 
using MAIPA method were 44%, 51% and 25% respectively. In conclusion the preference of 
MAIPA method is the detection of very small amount of antibody. Since MAIPA is the specific 
method for the detection of antibody against glycoprotein antigens, it has the advantage of 
differentiating immune and non-immune thrombocytopenia. 
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INTRODUCTION 
     Autoimmune thrombocytopenia purpura 
(ITP) is an autoimmune disease characterised 
by loss of self tolerance leading to the 
production of autoantibodies directed against 
platelet antigens [1,2,3]. The autoantibodies 
produced against platelet glycoproteins are able 
to bind to platelet membranes, initiating 
pathways that result in dysfunction and 
destruction of platelets and clinical singes. 
These include pethechiae, ecchimosis, and 
bleeding in some patients [3, 4]. Around 85% of 
platelet autoantigens lie on the platelet 
GPIIb/IIIa, GPIb/IX or GP Ia/IIa complexes, 
and 15% of them are found on other membrane 
glycoproteins [4]. Antiplatelet antibodies have 
been found in the sera of up to 80% of chronic 
ITP patients. However, despite many studies on 
antiplatelet antibodies, characterization of 
binding and evaluation of antiplatelet 
glycoproteins utoantibodies remain poor [5] and 
many questions remain unanswered [3].This 
study has determined and characterized the 
antiplatelet GPs in children with ITP.  
 
MATERALS AND METHODS 
 
Patients 
      47 children who were hospitalized with 
clinical signs of ITP in Mofid children hospital 
during 18 months, 38 of them were under study 
in our project. The physician in clinic recorded 
the patients' information including age, gender, 
history and clinical signs such as petechiae, 
purpura and ecchymosis in a standard format. 
All the relatives gave us consent to take blood 
sample from their children. 
 






      For platelet count, 2ml anticoagulated 
[Ethylen Diamine Tetraacetic Acid (EDTA)] 
blood was collected and counted by a cell 
counter (Sysmex). To detect anti-platelet 
glycoproteins antibodies, 3 ml serum was 
obtained from patients' clotted blood and 
aliquoted into two tubes and stored in freezer. 
 
Preparation of whole platelets 
     Anti-coagulated [Acid Citrate Dextrose 
(ACD)] blood was collected  from healthy O 
negative volunteers and centrifuged at 200 g for 
10 min. The platelet-rich plasma (PRP) was 
removed and recentrifuged at 1200 g for 10 
min. After four time washing with phosphate 
buffer saline (PBS) pH 7.4, the sedimented 
platelets were resuspended in buffer containing 
10% dimethylethyl sulfoxide (DMSO) and 
aliquoted into a cryotubes and stored in liquid 
nitrogen. 
 
Anti-platelet antibodies detection 
     ELISA plate was coated with 50 µL of 
washed platelet suspension containing 3×10
8
 
platelets in bicarbonate buffer (pH 8.6) in each 
well or 100 l of platelet lysate (200 g/ml) and 
incubated at 4C overnight. The following day 
plate was centrifuged at 2000 g for 5 minutes. 
After washing and blocking with 3% BSA in 
PBS and incubating for an hour at room 
temperature (RT), 100 µL of diluted patients 
and controls sera (1:10 diluted in PBS) were 
added and the plate was incubated for an hour at 
37
 
C.  The unbound anti-platelet antibodies 
were removed by washing four times with PBS 
0.05% Tween 20 (PBST washing buffer). 100 
µL Goat antihuman HRP-conjugated antibody 
(1: 50 000 diluted in PBS) ((Serotech Co. UK)) 
was added to each well and incubated at RT for 
an hour. The plate was washed five times with 
washing buffer then 100 µL of substrate 
[Tetramethylbenzidine (TMB) sigma] was 
added and the plate incubated for 30 min in a 
dark place. The reaction was stopped by adding 
100 µL of 3 M HCL, and the OD was measured 
at 650 nm. 
 
MAIPA (Monoclonal Antibody 
Immobilization of Platelet Antigens) 
     ELISA plate was coated with 100 µL of 
Goat anti mouse IgG [final concentration 5 
ug/ml diluted in Carbonate Bicarbonate Buffer 
(CBB) pH 8.6] in each well and incubated 
overnight at 4
oC
.  After washing with Tris 
Buffer Saline (TBS), the plate was blocked with 
200 µL of 3% BSA in PBS and incubated for an 
hour at room temperature (RT). 100 µL of 
washed O negative platelets suspension 
containing 5×10 
11
/ L were added to the tubes 
which were blocked with 50 µL 3% BSA and 
incubated for an hour with 100 µL of patients 
and controls serum for an hour at 37
 
C.  40 µL 
of  each monoclonal mouse anti platelet-
glycoproteins [ IIb/IIIa, Ib/IX and IIa/Ia  ( 
Novacastra UK)] with  final concentration of 20 
µg/ml diluted in PBS were added to the 
individual tubes containing mixture of washed 
platelets and patients or controls sera and 
incubated at 37 C for 30 minutes. The unbound 
human anti platelet-glycoproteins were removed 
by washing three times with TBS 0.05% Tween 
20 (TBST washing buffer). 100 µL of lysis 
buffer (TBS containing 0.05% Nonidet P-40 
Sigma) were added to each tubes and incubated 
for 30 minutes at 37 C.  
To prevent protein destruction, anti-protease 
agents was added to lysis buffer.  After 
centrifuging all tubes at 14000 g for 30 minutes 
at 4 C, 100 µL of supernatant was added to 
each well which were coated with anti-mouse 
antibody and incubated at 4 C for 90 minutes. 
The plate was washed four times with washing 
buffer and 100 µL of Goat antihuman HRP-
conjugated antibody (1: 50 000 diluted in PBS) 
(Serotech Co. UK)) was added to each well and 
incubated at RT for an hour. The plate was 
washed five times with washing buffer. 100 µL 
of substrate (TMB) was then added and the 
plate incubated for 30 min in a dark place. The 
reaction was stopped by adding 100 µL of 3 M 
HCL, and the OD was measured at 650 nm. 
 
RESULTS 
     In this project the goal of our study is to 
determine anti-platelet GPs antibody in children 
with ITP. 38 patients and 12 healthy individuals 
were included in our study as negative controls. 
68% of patients were girls and 32% boys and 
their age ranges between less than one year and 
up to sixteen years. The clinical signs were 
variable including 15 individuals only with 
petechiae, 11 of them not only with petechiae, 
but also with purpura and 8 of them with 
ecchymosis signs, and finally 4 of them were 
found out with severe bleeding from gums and 
urethral tract. 
     Figure 1 shows more details about clinical 
signs in ITP patients. Peripheral platelet count 





     ranges from less than 3×10
9








Figure 1. A pie chart of the ITP Patients' Clinical signs 
 
Table No 1 shows more details about 
platelet count in patients. The results with 
ELISA indicated that anti-platelet 
antibodies in sera of all patients either with 
clinical signs and low platelets count or just 
low platelets count reacted strongly with 
whole platelet antigens. 
 




     It should be mentioned that we used 
peroxidase activity to calculate level of 
antibody instead of OD by following formula;  
 
Percent change = OD sample – OD control / 
OD control × 100 
 
The mean controls absorbance was used as 
normal value. We also used the mean controls 
antibody level with three standard deviation 
(mean+3SD) as the cut-off. The anti-platelet 
antibodies level of each sample above the cut 
off was assumed as antibody positive. 
Out of 38 patients, 63.5% had anti-platelet 
antibody positive with mean platelet count of 
41.5×10
9
/L using non parametric spearman 
coefficient, it was statistically shown that there 
was a significant correlation between clinical 
signs and antibodies level in patients (r = 0.45, 
P<0.05).  
      Figure 2 shows the anti- platelet antibodies 
in ITP patients. 
 
 
Figure 2. ITP Patients who were Anti-platelet antibodies 
positive against whole platelet ( Anti-platelet antibodies 
against platelet antigens of 63.5% of patients were detected 
(green color).  
 
The determination of anti-platelet GP 
antibodies  
      Using MAIPA method, antibodies in 
patients' sera were analyzed against three most 
important platelet glycoproteins  ( GP IIb/IIIa, 
IIa/Ia, Ib/IX).  Result was shown that 48% of 
patients were anti-GP  
IIb/IIIa antibody positive with mean platelet 
count of 38×10
9
/L. 54% were anti-GP Ib/IX 
positive with mean platelet count of 50×10
9
/L. 
The correlation between anti-GP Ib/IX positive 
and clinical signs was 0.2. Out of 38 patients 
only 25% were anti GP-Ia/IIa positive with 
mean platelet count of 48×10
9
/L. Using non 
parametric spearman coefficient, it was 
statistically shown that a significant correlation 
was seen between increased anti-GP Ia/IIa level 
and the platelet count in patients (r= 0.35, P< 
0.05).  





Figure 3.  ITP Patients who were shown antibodies 
positive against platelet glycoproteins. 
 
DISCUSSION 
      Anti-platelet antibodies react against platelet 
glycoproteins and cause autoimmune 
thrombocytopenia purpura (ITP). ITP is an 
autoimmune disease characterized by platelet 
destruction, accompanied by increased bleeding 





and haemorrhage [3, 4, 7]. In order to further 
characterize the function of autoantibodies 
against platelet glycoproteins in ITP patients, 
this study has investigated the following:  first 
the determination of anti-platelet antibodies 
using ELISA method, next detection of these 
antibodies by flow cytometry and compares 
their results with ELISA assay and finally 
detection of anti-GPs antibodies by MAIPA. 
The most clinical signs were petechiae and 
purpura and in 4 individuals severe bleeding. 
The platelet count was shown that more than 
50% of patients had platelet count < 30×10
9
/L 
which correlates with the severity of clinical 
signs. In some patients not only the platelet 
count was decreased but they also had anemia 
due to low hemoglobin concentration and RBC 
count. Normochromic normocytic anemia in 
these patients may be due to blood loss as a 
result of hemorrhage and massive ecchymosis 
or probably they had ITP with autoimmune 
hemolytic anemia( Evans syndrome)[8]. 
The mean result of controls anti-platelet 
antibodies+3SD (Mean+3SD) was used as the 
cut off, and the patients with anti-platelet 
antibodies above the cut off were assumed as 
antibody positive. 63.5% out of 38 patients in 
our assay were anti-platelet antibodies positive 
with the mean platelet count of 41.5×10
9
/L 
which shows a good correlation between 
decreased circulating platelets and increased 
antibodies levels in comparison with anti-
platelet negative patients. There was a positive 
correlation between increased serum anti-
platelet antibodies and clinical signs. In some 
patients there was neither correlation between 
anti-platelet antibodies and platelet count nor 
clinical sings. It could be due to acute phase of 
disease which the antibodies absorbed on 
platelets membrane and removed from 
circulation by phagocyte system [8]. On the 
other hand, detection of auto antibodies on 
platelet surface due to platelet structure is not 
easy [9]. Cordiano and et al. has reported that 
56% of 32 ITP patients were anti-platelet 
antibodies positive by ELISA method [12]. The 
results showed that 48% of patients were anti-
GPIIb/IIIa positive by MAIPA method. The 
correlation between anti-GPIIb/IIIa antibody 
and antibodies against whole platelet antigens 
was 0.4. Van Leeuwen has reported that 80% of 
42 ITP patients were anti-GPIIb/IIIa positive 
[13].  
In our study 54% of patients were anti-GPIb/IX 
positive. It should be mentioned that 35% of 
patients had both anti-GPIIb/IIIa and Ib/IX 
antibodies in their sera. Fuji Sawa and 
colleagues have reported that 75% of ITP 
patients have anti-GP IIb/IIIa and Ib/IX [14-16]. 
In 25% of patients we have found anti-GPIa/IIa 
in sera and correlation between level of anti-
GPIa/IIa and low platelet count was 0.4. 
However the determination of antibodies 
against the platelet glycoproteins by MAIPA is 




     Since coating platelets at the bottom of 
ELISA plate is difficult, we have modified the 
method by centrifuging the plate and fixing 
them with Glutaraldehyde. 
Instead of using optical density (OD) for 
analysis of the data which can not differentiate 
low absorption, we used percentage of 
peroxidase activity. 
The preference of MAIPA method is due to the 
large amount of Ag-Ab complex in the 
supernatant of platelet lysate (the second 
process) and the detection of a trace amount of 
antibody. 
Since MAIPA is the specific method for 
detection of antibody against glycoprotein 
antigens, it has the advantage of differentiating 
immune from non-immune thrombocytopenia. 
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